Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
29 December 1978Website:
http://www.danaher.comNext earnings report:
30 January 2025Last dividends:
27 September 2024Next dividends:
N/APrice
after hours | 19 min agoAnalysts recommendations
Institutional Ownership
Included in screeners
DHR Latest News
Danaher announced decent earnings for the third quarter, and "cautious" is likely the best word to describe the report. The company is back to growing, and their future outlook appears positive, but the management is hesitant to provide specific figures to support their optimism. I discuss the possible reasons for this cautious approach in the article.
On Tuesday, Danaher Corp DHR announced that its sales for the third quarter reached $5.79 billion, which is a 3% increase compared to the same period last year. This figure surpassed the expected consensus of $5.59 billion.
DHR's earnings and sales for the third quarter exceeded expectations, thanks to the strong results from its Life Sciences and Diagnostics divisions.
The Danaher Corporation (NYSE:DHR) held its Q3 2024 Earnings Call on October 22, 2024, at 8:00 AM ET. Key participants included John Bedford, the VP of Investor Relations, Rainer Blair, the President and CEO, and Matt McGrew, the EVP and CFO. The call was facilitated by Ashley, who welcomed everyone to the conference.
Danaher (DHR) reported quarterly earnings of $1.71 per share, which is higher than the Zacks Consensus Estimate of $1.56 per share. This is a decrease compared to earnings of $2.02 per share from the same period last year.
On Tuesday, Danaher exceeded Wall Street's expectations for its third-quarter profits due to high demand in its diagnostics and bioprocessing sectors, as well as growth in its molecular testing division.
On October 22, 2024, Danaher Corporation (NYSE: DHR) shared its financial results for the quarter that ended on September 27, 2024. This announcement focuses solely on the company's ongoing operations, unless stated otherwise.
Instead of just focusing on Wall Street's predictions for Danaher (DHR), it's important to examine some of its key metrics to better understand how the company might perform in the quarter that ended in September 2024. This deeper analysis can provide valuable insights into its potential success.
DHR is expected to gain from the strong performance of its clinical diagnostics division, the acquisition of Abcam, and policies that favor shareholders. However, there are still worries about the weaker performance of the Instrument unit.
I maintain my 'Strong Buy' recommendation for Danaher, setting a one-year price target of $310 per share due to improvements in bioprocessing and increased market share in molecular testing. The bioprocessing sector is experiencing strong growth in orders, particularly with a recovery in China, and this trend is likely to continue into Q3 and FY25. Additionally, Cepheid's recent market share gains in molecular testing, such as the FDA approval for its Hepatitis C RNA test, showcase Danaher's potential for innovation and growth.
What type of business is Danaher?
Danaher Corporation is a global diversified conglomerate, one of the world leaders in scientific research and development, and production of innovative products and solutions for multiple industries. Founded in 1969 as an investment fund, it has since undergone a series of transformations (mergers and acquisitions). Today, the company develops, manufactures, and sells professional, medical, industrial, and commercial products and services, characterized by strong brands, innovative technologies, and leading market positions. Danaher's headquarters is located in Washington. Research, manufacturing, sales, service, and administrative centers are located in more than 60 countries - in Europe, Asia, South and North America, and Australia.
What sector is Danaher in?
Danaher is in the Healthcare sector
What industry is Danaher in?
Danaher is in the Diagnostics & Research industry
What country is Danaher from?
Danaher is headquartered in United States
When did Danaher go public?
Danaher initial public offering (IPO) was on 29 December 1978
What is Danaher website?
https://www.danaher.com
Is Danaher in the S&P 500?
Yes, Danaher is included in the S&P 500 index
Is Danaher in the NASDAQ 100?
No, Danaher is not included in the NASDAQ 100 index
Is Danaher in the Dow Jones?
No, Danaher is not included in the Dow Jones index
When was Danaher the previous earnings report?
No data
When does Danaher earnings report?
The next expected earnings date for Danaher is 30 January 2025